Peptide field guide
Pinealon
A short peptide (often discussed as an EDR peptide family) that appears in gerontology and neurobiology literature; widely marketed online for sleep and brain benefits with limited modern clinical evidence.
What it is
Pinealon is a short peptide often discussed in relation to the EDR peptide family (Glu-Asp-Arg).
It appears in parts of the gerontology and neurobiology literature, and it is heavily marketed online for sleep quality and cognitive benefits.
Why people care
The story being sold is that pinealon improves “sleep architecture” and brain recovery, sometimes with claims that effects persist after stopping.
The responsible framing is simpler: the molecule has a literature footprint, but the strongest modern clinical evidence for many popular claims is limited.
Evidence landscape
- Preclinical and gerontology-oriented papers exist.
- Clear, modern human trials with objective sleep endpoints are not prominent in PubMed search results.
Safety reality
There is no large, modern safety database supporting broad use for sleep or longevity. We do not provide dosing advice.
References
- “EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease.” Molecules (2020). https://pubmed.ncbi.nlm.nih.gov/33396470/
- Adv Gerontol (2015) indexed pinealon-related work: https://pubmed.ncbi.nlm.nih.gov/28509493/